5 completed, 1 not yet recruiting, 1 terminated, 1 unknown. 9 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 5, Not yet recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 6 | Completed 3, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
Follow Hearing Loss, Sudden: new trials by email Literature Review of Hearing Loss, Sudden trials Research Report on Hearing Loss, Sudden
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Verification of the Efficacy/Safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss Dexamethasone, Hyaluronic acid, Indocyanine green(ICG) - Hearing Loss, Sensorineural, Hearing Loss, Sudden | Phase 1 / Phase 2 | Withdrawn | Seoul National University Hospital | 2026-12-15 | 2026-05-22 | |
| Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss Tympanic injection of hUC-MSC-sEV-003 (small extracellular vesicles) at low doses, Tympanic injection of hUC-MSC-sEV-003 (small extracellular vesicles) at moderate doses, Tympanic injection of hUC-MSC-sEV-003 (small extracellular vesicles) at high doses - Sudden Hearing Loss, Extracellular Vesicles | Phase 1 / Phase 2 | Not yet recruiting | The Affiliated Hospital of Qingdao University | 9 | 2026-02-28 | 2026-03-25 |
| A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients NS101, Placebo - Seneorineural Deafness, Sudden Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Neuracle Science Co., LTD. | 113 | 2024-02-15 | 2026-11-02 |
| Verification of the Efficacy/safety of the Intratympanic Drug Delivery for Hearing Loss Dexamethasone, Hyaluronic acid - Hearing Loss, Sudden, Hearing Loss, Ototoxic | Phase 1 / Phase 2 | Completed | Seoul National University Hospital | 15 | 2021-07-22 | 2024-10-24 |
| Phase I Clinical Study of HY01 in Patients HY01 - Sudden Sensorineural Hearing Loss | Phase 1 | Unknown | Heyu (Suzhou) Pharmaceutical Technology Co., Ltd | 12 | 2021-06-23 | 2021-07-14 |
| FX-322 in Adults With Severe Sensorineural Hearing Loss FX-322, Placebo - Hearing Loss, Sensorineural, Noise Induced Hearing Loss | Phase 1 | Completed | Frequency Therapeutics | 31 | 2020-11-02 | 2022-02-01 |
| FX-322 in Adults With Age-Related Sensorineural Hearing Loss FX-322, placebo - Presbycusis, Hearing Loss, Sensorineural | Phase 1 | Completed | Frequency Therapeutics | 30 | 2020-09-17 | 2022-05-25 |
| Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing Loss anakinra - Hearing Loss, Sudden | Phase 1 / Phase 2 | Terminated | Andrea Vambutas | 2 | 2013-10-01 | 2017-03-13 |
| A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease Anakinra - Sensorineural Hearing Loss, Autoimmune Inner Ear Disease | Phase 1 / Phase 2 | Completed | Andrea Vambutas | 13 | 2011-06-01 | 2018-01-10 |
Hearing Loss, Sensorineural (5) · Hearing Loss, Noise-Induced (3) · Meniere Disease (2) · Hearing Loss (1) · Hearing Loss, Hidden (1) · Presbycusis (1)
Ear Diseases (9) · Hearing Disorders (9) · Nervous System Diseases (9) · Neurologic Manifestations (9) · Otorhinolaryngologic Diseases (9) · Pathological Conditions, Signs and Symptoms (9) · Sensation Disorders (9) · Signs and Symptoms (9) · Hearing Loss (8) · Endolymphatic Hydrops (2) · Labyrinth Diseases (2) · Hearing Loss, Sensorineural (1)
Dexamethasone (2) · Hyaluronic Acid (2) · Interleukin 1 Receptor Antagonist Protein (2) · Indocyanine Green (1)
Andrea Vambutas (2) · Frequency Therapeutics (2) · Seoul National University Hospital (2) · Heyu (Suzhou) Pharmaceutical Technology Co., Ltd (1) · Neuracle Science Co., LTD. (1) · The Affiliated Hospital of Qingdao University (1)
United States (4) · China (2) · South Korea (2)
Andrea Vambutas, MD (2) · Carl LeBel, PhD (2) · Dong Pin, Doctor (1) · Joseph Park, M.D. (1)
R33DC011827 (1)